Go Pro

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:GRTS

Gritstone bio (GRTS) Stock Price, News & Analysis

Gritstone bio logo

About Gritstone bio Stock (NASDAQ:GRTS)

Key Stats

Today's Range
$0.03
$0.03
50-Day Range
$0.03
$0.63
52-Week Range
$0.03
$3.17
Volume
N/A
Average Volume
7.01 million shs
Market Capitalization
$3.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Receive GRTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gritstone bio and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GRTS Stock News Headlines

Gritstone Bio sets sale of assets through Bankruptcy Court
Gritstone Oncology Inc (GRTSQ)
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
Gritstone bio, Inc. (GRTSQ)
Firm Retention Summary: Gritstone bio
Gritstone Oncology Pursues Restructuring Through Chapter 11
Why Gritstone Bio (GRTS) Stock Is Down 64% Today
See More Headlines

GRTS Stock Analysis - Frequently Asked Questions

Gritstone bio, Inc. (NASDAQ:GRTS) announced its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.12. The company earned $0.92 million during the quarter, compared to the consensus estimate of $2.77 million. Gritstone bio had a negative net margin of 910.50% and a negative trailing twelve-month return on equity of 328.51%.

Gritstone bio (GRTS) raised $85 million in an initial public offering (IPO) on Friday, September 28th 2018. The company issued 6,100,000 shares at $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays served as the underwriters for the IPO and BTIG was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Gritstone bio investors own include Waste Connections (WCN), AUO (AUOTY), DiamondRock Hospitality (DRH), The RMR Group (RMR), Voyager Therapeutics (VYGR), American Water Works (AWK) and iShares Micro-Cap ETF (IWC).

Company Calendar

Last Earnings
8/13/2024
Today
8/03/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:GRTS
CIK
1656634
Fax
N/A
Employees
190
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.24)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$138.49 million
Net Margins
-910.50%
Pretax Margin
-910.50%
Return on Equity
-328.51%
Return on Assets
-82.53%

Debt

Debt-to-Equity Ratio
1.83
Current Ratio
2.54
Quick Ratio
2.54

Sales & Book Value

Annual Sales
$496 thousand
Price / Sales
7.05
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.54 per share
Price / Book
0.06

Miscellaneous

Outstanding Shares
108,569,000
Free Float
111,837,000
Market Cap
$3.50 million
Optionable
No Data
Beta
0.49
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (NASDAQ:GRTS) was last updated on 8/3/2026 by MarketBeat.com Staff.
From Our Partners